BI 2536

Catalog No.S1109

Molecular Weight(MW): 521.66

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Cited by 134 Publications

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2017, 548(7668):466-470

PubMed: 28759889 ( click the link to review the publication )

Cancer Discov, 2014, 4(11):1281-9

PubMed: 25107667 ( click the link to review the publication )

Cell, 2011, 4(10):1087-96

PubMed: 22078882 ( click the link to review the publication )

Cancer Cell, 2010, 18(6):641-54

PubMed: 21156286 ( click the link to review the publication )

Cell Res, 2019, 29(7):562-578

PubMed: 31201382 ( click the link to review the publication )

Mol Cell, 2019, 73(5):915-929

PubMed: 30849395 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3779

PubMed: 31439829 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav0318

PubMed: 31803841 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

EBioMedicine, 2019, 41:244-255

PubMed: 30876762 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Ther Adv Med Oncol, 2019, 11:1758835919846375

PubMed: 31156720 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz051

PubMed: 31174204 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1615-1627

PubMed: 31227645 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Mol Cancer Res, 2019, doi: 10

PubMed: 31604847 ( click the link to review the publication )

Lab Invest, 2019, 99(9):1275-1286

PubMed: 30996295 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )
Nucleic Acids Res, 2018, 46(20):10724-10739

PubMed: 30202980 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Theranostics, 2018, 8(10):2884-2895

PubMed: 29774081 ( click the link to review the publication )

Cancer Res, 2018, 78(2):572-583

PubMed: 29180474 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

Sci Signal, 2018, 11(530)

PubMed: 29764992 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(11):5300-5310

PubMed: 30133120 ( click the link to review the publication )

Hum Gene Ther, 2018, 29(8):886-901

PubMed: 29641320 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )

Transl Oncol, 2018, 11(4):852-863

PubMed: 29753186 ( click the link to review the publication )

Cell Res, 2017, 27(2):274-293

PubMed: 27958289 ( click the link to review the publication )

Mol Cell, 2017, 67(4):579-593

PubMed: 28781233 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1506

PubMed: 29138396 ( click the link to review the publication )

Nat Commun, 2017, 8:15289

PubMed: 28474672 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(2):431-444

PubMed: 28922657 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

FEBS J, 2017, 284(23):4035-4050

PubMed: 28985013 ( click the link to review the publication )
J Biol Chem, 2017, 292(36):15028-15038

PubMed: 28739871 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 484(4):864-870

PubMed: 28188792 ( click the link to review the publication )

Oncotarget, 2017, 9(13):10920-10933

PubMed: 29541386 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37633-37645

PubMed: 28430578 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:10818

PubMed: 26912231 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(6):411-8

PubMed: 27043190 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):48-59

PubMed: 26586723 ( click the link to review the publication )

J Virol, 2016, 90(6):2794-805

PubMed: 26719254 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M115.712745

PubMed: 27325694 ( click the link to review the publication )

J Biol Chem, 2016, 291(20):10904-15

PubMed: 27002159 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0153818

PubMed: 27097159 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26580-92

PubMed: 27058891 ( click the link to review the publication )

Head Neck, 2016, 10.1002/hed.24349

PubMed: 26713885 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(8):1024-35

PubMed: 26192437 ( click the link to review the publication )
Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms8217

PubMed: 26147444 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Nat Commun, 2015, 6:8077

PubMed: 26293378 ( click the link to review the publication )

Nat Commun, 2015, 6:6946

PubMed: 25897860 ( click the link to review the publication )

Nat Commun, 2015, 6:10076

PubMed: 26647647 ( click the link to review the publication )

Nat Commun, 2015, 6:10072

PubMed: 26656453 ( click the link to review the publication )

Cancer Res, 2015, 75(2):405-14

PubMed: 25480943 ( click the link to review the publication )

J Control Release, 2015, 204:20-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 357(2):591-601

PubMed: 25524551 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 14(4):946-60

PubMed: 25659891 ( click the link to review the publication )

J Neurochem, 2015, 10.1111/jnc.13085

PubMed: 25727910 ( click the link to review the publication )

J Biol Chem, 2015, 290(5):3033-44

PubMed: 25505268 ( click the link to review the publication )

Mol Biol Cell, 2015, 26(3):440-52

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(2):219-31

PubMed: 25607646 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5275-91

PubMed: 25779659 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(6):538-49

PubMed: 24776885 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(12):3211-21

PubMed: 24771642 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5878-90

PubMed: 25125659 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 13(5):1054-66

PubMed: 24748653 ( click the link to review the publication )
J Biol Chem, 2014, 289(38):26344-56

PubMed: 25100726 ( click the link to review the publication )

J Biol Chem, 2014, 289(18):12313-29

PubMed: 24634213 ( click the link to review the publication )

J Biol Chem, 2014, 289,14066-14074

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14066-74

PubMed: 24706748 ( click the link to review the publication )

Cell Cycle, 2014, 13(2):303-14

PubMed: 24247149 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3867-77

PubMed: 25558830 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115228

PubMed: 25542032 ( click the link to review the publication )

PLoS One, 2014, 8(10):e77053

PubMed: 24204733 ( click the link to review the publication )

Oncotarget, 2014, 5(3):667-78

PubMed: 24525428 ( click the link to review the publication )

The University of Queensland, 2014, Fawzi Faisal A. Bokhari

PubMed: ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(32):13026-31

PubMed: 23878225 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(2):813-23

PubMed: 23144294 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.518

PubMed: 24317508 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(3):461-9

PubMed: 23146687 ( click the link to review the publication )

J Biol Chem, 2013, 288(33):23765-75

PubMed: 23814058 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14158-69

PubMed: 23504319 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(13):8353-63

PubMed: 24366665 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77390

PubMed: 24155950 ( click the link to review the publication )
J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Biol Open, 2013, 2(5):479-86

PubMed: 23789096 ( click the link to review the publication )

J Biol Chem, 2012, 287(6):4376-85

PubMed: 22184120 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17088-99

PubMed: 22467873 ( click the link to review the publication )

Cell Cycle, 2012, 11(3):543-53

PubMed: 22262171 ( click the link to review the publication )

PLoS One, 2012, 7(6):e38838

PubMed: 22701722 ( click the link to review the publication )

Biotechniques, 2012, 10.2144/000113866

PubMed: ( click the link to review the publication )

Biotechniques, 2012, 53(1)

PubMed: 26307252 ( click the link to review the publication )

Nat Cell Biol, 2011, 13(10):1265-71

PubMed: 21874008 ( click the link to review the publication )

Cancer Res, 2011, 71(4):1385-95

PubMed: 21303981 ( click the link to review the publication )

Cancer Res, 2011, 71(17):5659-69

PubMed: 21693658 ( click the link to review the publication )

J Cell Biol, 2011, 193(6):1083-99

PubMed: 21646404 ( click the link to review the publication )

Oncogene, 2011, 30(46):4666-77

PubMed: 21602893 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(9):1886-95

PubMed: 21654832 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Features

The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.

Targets

PLK1 ^[1] (Cell-free assay)	PLK2 ^[1] (Cell-free assay)	PLK3 ^[1] (Cell-free assay)
0.83 nM	3.5 nM	9.0 nM

In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. ^[1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PSN1	NXXLSXhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTBwMEC3O\|Yh\|ryP	MkS1V2FPT0WU
ACN	M1;se2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTjVHdKSzVyPUCuNFA5PDNizszN	Mn7TV2FPT0WU
TE-8	Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1i4[GlEPTB;MD6wNFk1OSEQvF2=	MUXTRW5ITVJ?
LC-2-ad	MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjITWM2OD1yLkCxNFk{KM7:TR?=	Mo\0V2FPT0WU
ALL-PO	M2HLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTBwMEGzJO69VQ>?	NFjONItUSU6JRWK=
EW-16	NU\SSoZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fNTmlEPTB;MD6wNVM{PiEQvF2=	NEP5[\|dUSU6JRWK=
KM12	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\zSWlEPTB;MD6wNVM1QCEQvF2=	NFrkTY1USU6JRWK=
GI-1	NYT5PGRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mly3TWM2OD1yLkCxN\|g{KM7:TR?=	NEjLVG9USU6JRWK=
LS-411N	M4HXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MliwTWM2OD1yLkCxOFA4KM7:TR?=	MWLTRW5ITVJ?
ES8	NGX2eJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DyfWlEPTB;MD6wNVQ6PCEQvF2=	NIDKb5BUSU6JRWK=
SNU-C2B	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mor6TWM2OD1yLkCxOVI3KM7:TR?=	MlviV2FPT0WU
CESS	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33ZVmlEPTB;MD6wNVYxOiEQvF2=	M4TiWnNCVkeHUh?=
697	M2HJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jFfWlEPTB;MD6wNVY3QCEQvF2=	MofhV2FPT0WU
NCI-H1963	M2\pXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrBT4NKSzVyPUCuNFE3PzNizszN	MmHVV2FPT0WU
IA-LM	MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzEVVN[UUN3ME2wMlAyPjh6IN88US=>	MkT0V2FPT0WU
SW954	M1K1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rUSmlEPTB;MD6wNVcxPSEQvF2=	Ml;MV2FPT0WU
RL95-2	MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHRO\|FpUUN3ME2wMlAyPzN6IN88US=>	NImwNWJUSU6JRWK=
LXF-289	Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXlTWM2OD1yLkCxO\|ch\|ryP	NUHvc2RRW0GQR1XS
OCUB-M	MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlq1TWM2OD1yLkCxPFI3KM7:TR?=	NHHRUZlUSU6JRWK=
RKO	M3LCcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTBwMEG5PFch\|ryP	NVLnUlN4W0GQR1XS
LOUCY	NVrFe5pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXz2eY5lUUN3ME2wMlAzODVizszN	M2X6fnNCVkeHUh?=
NOS-1	NXTVWFRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LYO2lEPTB;MD6wNlA6OyEQvF2=	MXXTRW5ITVJ?
A4-Fuk	M3ji[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTBwMEKyNVgh\|ryP	MoPmV2FPT0WU
A388	MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDPeZhKSzVyPUCuNFIzOjdizszN	NEXMd3VUSU6JRWK=
TE-9	Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLWTlJxUUN3ME2wMlAzOjZzIN88US=>	NUHIRotHW0GQR1XS
KURAMOCHI	NYOy[JNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1W2b2lEPTB;MD6wNlI5PSEQvF2=	NGTWZpZUSU6JRWK=
KALS-1	MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXyzNoZmUUN3ME2wMlAzOzN6IN88US=>	NUj0[lhjW0GQR1XS
HOP-62	MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTBwMEK0NkDPxE1?	M362OnNCVkeHUh?=
RPMI-8402	MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTBwMEK1NFgh\|ryP	MV;TRW5ITVJ?
TE-1	NYHXfGdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrNenVKSzVyPUCuNFI2OTJizszN	NXnNWZp5W0GQR1XS
CCRF-CEM	NFOwRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIixfFFKSzVyPUCuNFI2PDNizszN	MXPTRW5ITVJ?
HUTU-80	M3[2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH:xWHFKSzVyPUCuNFI3OjRizszN	NIHxTGtUSU6JRWK=
NCI-H1648	NUHqWo1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfFepBKSzVyPUCuNFI3PDdizszN	MVTTRW5ITVJ?
HCE-4	NEHmbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPINJZKSzVyPUCuNFI3QDJizszN	MVfTRW5ITVJ?
ETK-1	MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTBwMEK3N\|Yh\|ryP	NF3xXHFUSU6JRWK=
TE-15	NYnLV4prT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTBwMEK3N\|gh\|ryP	MkHOV2FPT0WU
BE-13	NG[yN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLzNnpKSzVyPUCuNFI4PCEQvF2=	Mk\KV2FPT0WU
KE-37	NV\HUWN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFSwdJlKSzVyPUCuNFI4PDFizszN	MVjTRW5ITVJ?
NCI-H1355	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TodGlEPTB;MD6wNlc5OyEQvF2=	Mo\oV2FPT0WU
TE-11	M{PvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGm5XHBKSzVyPUCuNFI5ODlizszN	NV;MbFlHW0GQR1XS
BL-70	NVrCZW5NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFz3SXZKSzVyPUCuNFI5PTdizszN	NXj6V\|FyW0GQR1XS
ES6	NUCxXpZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjIS49KSzVyPUCuNFI5QDFizszN	NILUUWFUSU6JRWK=
GT3TKB	NF3Pbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvDTWM2OD1yLkCyPVU{KM7:TR?=	MV7TRW5ITVJ?
LB647-SCLC	M4THcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3LTWM2OD1yLkCzNVk2KM7:TR?=	NVq2ZXpVW0GQR1XS
NB13	NFy4cINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTBwMEOzNVYh\|ryP	NYPieo93W0GQR1XS
ST486	NYS5UYxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTBwMEOzN\|ch\|ryP	NEnwZ5FUSU6JRWK=
NCI-H82	NUHte4M4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYq0RlZIUUN3ME2wMlA{OzR\|IN88US=>	Ml22V2FPT0WU
NTERA-S-cl-D1	NHzWS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjWOHp6UUN3ME2wMlA{Ozl7IN88US=>	MmPRV2FPT0WU
ES4	Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITifGdKSzVyPUCuNFM1PjNizszN	NHS4c4xUSU6JRWK=
SK-NEP-1	NEfEb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\5eGlEPTB;MD6wN\|Q6QSEQvF2=	MVnTRW5ITVJ?
Becker	NVG3b2lqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fiVmlEPTB;MD6wN\|U2PSEQvF2=	NWDjd2lQW0GQR1XS
A101D	NXTjOnlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTBwMEO3OFgh\|ryP	M{jIVXNCVkeHUh?=
SK-UT-1	NXrxbFhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\oTWM2OD1yLkCzO\|c1KM7:TR?=	Mn;OV2FPT0WU
SW982	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fNfWlEPTB;MD6wN\|c6KM7:TR?=	Ml7PV2FPT0WU
TE-10	NGHOSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2iyR2lEPTB;MD6wOFA1PiEQvF2=	M1PSOXNCVkeHUh?=
OVCAR-4	NXzvNlgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LzTmlEPTB;MD6wOFA2QSEQvF2=	NWTiTWprW0GQR1XS
KP-N-YS	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTBwMESwPFUh\|ryP	M3\mcnNCVkeHUh?=
BL-41	NY\YZmk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TGUGlEPTB;MD6wOFEzPSEQvF2=	M3nxNXNCVkeHUh?=
MZ1-PC	M{\4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmOyTWM2OD1yLkC0NVI4KM7:TR?=	MVfTRW5ITVJ?
PF-382	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV21[\|RTUUN3ME2wMlA1OTl6IN88US=>	NHvLcGFUSU6JRWK=
MOLT-13	MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1S1O2lEPTB;MD6wOFI{QCEQvF2=	NY\yWldXW0GQR1XS
HCC1599	M{P1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DET2lEPTB;MD6wOFI2QCEQvF2=	NVLrV2dSW0GQR1XS
IST-MEL1	NXHqOmxST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTBwMES0OFIh\|ryP	Mm\qV2FPT0WU
LU-139	Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTBwMES0OFIh\|ryP	MXfTRW5ITVJ?
MS-1	MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoflTWM2OD1yLkC0O\|AyKM7:TR?=	NVT1UG5vW0GQR1XS
MFH-ino	NX3KO\|Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DsTWlEPTB;MD6wOVAxOyEQvF2=	MmPyV2FPT0WU
IMR-5	NIjkTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTBwMEWwNlEh\|ryP	NFrYXWZUSU6JRWK=
TE-5	NEH6Z\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrPTWM2OD1yLkC1NFY{KM7:TR?=	NVLQSmlFW0GQR1XS
DJM-1	NIfBbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2L0W2lEPTB;MD6wOVE1OiEQvF2=	NIHpTldUSU6JRWK=
NB17	NWfXcYtbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPDUnBKSzVyPUCuNFUzODdizszN	MXzTRW5ITVJ?
KARPAS-45	M2H0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDVNm9KSzVyPUCuNFU{PThizszN	NELweXVUSU6JRWK=
TGBC1TKB	M3XoSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jye2lEPTB;MD6wOVQxPSEQvF2=	Mkn0V2FPT0WU
ML-2	M4\zOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2KwR2lEPTB;MD6wOVQyPCEQvF2=	NX3vV3VYW0GQR1XS
no-10	NXn0Vm1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\mVGlEPTB;MD6wOVQ4PCEQvF2=	M2ntWHNCVkeHUh?=
CTV-1	M4\sO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\1TWM2OD1yLkC1OVAzKM7:TR?=	NYewV5FqW0GQR1XS
SJSA-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPUbodKSzVyPUCuNFU2OiEQvF2=	NVKzXFBTW0GQR1XS
HC-1	NYLNcZgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjudWRGUUN3ME2wMlA2PTl5IN88US=>	NV7hNmd1W0GQR1XS
TE-12	M4TTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTBwMEW2NVMh\|ryP	MY\TRW5ITVJ?
KY821	M13Gd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITvWXZKSzVyPUCuNFU3OzJizszN	NUPBZ\|VzW0GQR1XS
TALL-1	NUnO[mRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXPZWNQUUN3ME2wMlA2PzB6IN88US=>	M3m5bHNCVkeHUh?=
DEL	NFnxfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWT2U5dSUUN3ME2wMlA2PzB7IN88US=>	M3Sw[3NCVkeHUh?=
TE-6	NWHDVlJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{D4[2lEPTB;MD6wOVczOiEQvF2=	MVHTRW5ITVJ?
SK-LMS-1	NWmyWIExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXu1WI04UUN3ME2wMlA2QDB3IN88US=>	NHjWSnJUSU6JRWK=
EW-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIP2S\|hKSzVyPUCuNFU5OzdizszN	NVXBVYJDW0GQR1XS
8-MG-BA	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTBwMEW4OVEh\|ryP	M2fFd3NCVkeHUh?=
NALM-6	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TmNWlEPTB;MD6wOVk4OyEQvF2=	NHO0RWdUSU6JRWK=
LB771-HNC	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrGTWM2OD1yLkC1PVc6KM7:TR?=	M{P0SXNCVkeHUh?=
HT-144	NH7DWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTBwME[xN{DPxE1?	MXrTRW5ITVJ?
KM-H2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mon4TWM2OD1yLkC2NlIyKM7:TR?=	Moq0V2FPT0WU
SF268	M{L3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1Ph[2lEPTB;MD6wOlI5PiEQvF2=	M1;Re3NCVkeHUh?=
RS4-11	MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGixRpFKSzVyPUCuNFY{ODRizszN	M2i1enNCVkeHUh?=
MHH-PREB-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVS5d\|YyUUN3ME2wMlA3OzF7IN88US=>	M2PmTHNCVkeHUh?=
ATN-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLWTWM2OD1yLkC2N\|Q2KM7:TR?=	NHr0O2NUSU6JRWK=
BB30-HNC	NUTzTVBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TQO2lEPTB;MD6wOlQ{PiEQvF2=	NGnaPItUSU6JRWK=
CPC-N	M{TEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHYSIxKSzVyPUCuNFY2OjRizszN	MYfTRW5ITVJ?
NB1	M{W5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3WwV2lEPTB;MD6wOlYyOyEQvF2=	NYS1b5FuW0GQR1XS
KS-1	MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXTTWM2OD1yLkC2O\|Q5KM7:TR?=	NVLP[Zl7W0GQR1XS
RXF393	MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3kcIVKSzVyPUCuNFY4PjRizszN	MlH1V2FPT0WU
IST-SL2	Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWSxb\|dtUUN3ME2wMlA4ODB2IN88US=>	Mnr4V2FPT0WU
GI-ME-N	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DMRmlEPTB;MD6wO\|I5PiEQvF2=	M3ThNnNCVkeHUh?=
VA-ES-BJ	M1TRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LpdGlEPTB;MD6wO\|Q4PSEQvF2=	MkG1V2FPT0WU
NCI-H1581	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHG5V5lKSzVyPUCuNFc1PzhizszN	MnvuV2FPT0WU
U-266	MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2WxVGlEPTB;MD6wO\|Q6PyEQvF2=	NFjKboVUSU6JRWK=
DMS-114	M3XyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHveWZKSzVyPUCuNFc2OjhizszN	NWnPUotmW0GQR1XS
NCI-H187	MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTBwMEe3NlYh\|ryP	MlPrV2FPT0WU
SW962	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HreWlEPTB;MD6wO\|g{QSEQvF2=	M3nzeXNCVkeHUh?=
MONO-MAC-6	NYP2RYp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDETWM2OD1yLkC3PVg3KM7:TR?=	MmfKV2FPT0WU
MOLT-16	NIHteGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTBwMEixNlEh\|ryP	NIjlS4pUSU6JRWK=
KNS-42	M3f6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHnTWM2OD1yLkC4NVYyKM7:TR?=	M1XqWnNCVkeHUh?=
CMK	NXzweZVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPlTWM2OD1yLkC4NlI2KM7:TR?=	M1nXSXNCVkeHUh?=
Ramos-2G6-4C10	NEWzVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfvb5FKSzVyPUCuNFgzOjVizszN	NHvtdmxUSU6JRWK=
Daudi	MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnUdHdKSzVyPUCuNFgzPTZizszN	MmXLV2FPT0WU
NCI-H510A	NHXQbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGS0OphKSzVyPUCuNFg{OzZizszN	NX22e3kyW0GQR1XS
LB831-BLC	NF;2VVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{H3OmlEPTB;MD6wPFU3OSEQvF2=	NG[4[4FUSU6JRWK=
HEL	M3HWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4G2dWlEPTB;MD6wPFY3QCEQvF2=	MUTTRW5ITVJ?
LU-134-A	MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjSTWM2OD1yLkC4O\|A5KM7:TR?=	NV7ENnU3W0GQR1XS
NCI-H1694	M2\nc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTBwMEi3OFQh\|ryP	M{LkfHNCVkeHUh?=
KGN	NFHjWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTBwMEi3OVkh\|ryP	NFy1NndUSU6JRWK=
A253	NG\UO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\zPWlEPTB;MD6wPFgzOiEQvF2=	M4iwbXNCVkeHUh?=
DG-75	NInZ[\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTBwMEi5NlIh\|ryP	M2LCbXNCVkeHUh?=
MOLT-4	NHPpZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTneI5UUUN3ME2wMlA5QTh\|IN88US=>	MYPTRW5ITVJ?
NCI-SNU-5	NU\XfoNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTBwMEmyOVgh\|ryP	NXP3WY5pW0GQR1XS
ONS-76	M3Wwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXG2cnVIUUN3ME2wMlA6Ojd4IN88US=>	NUTMUWdVW0GQR1XS
NCI-H446	M3Lv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPVZZZKSzVyPUCuNFk1PjJizszN	MmfjV2FPT0WU
COR-L279	NYDNS4V6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrteGdKSzVyPUCuNFk2PTZizszN	MYjTRW5ITVJ?
Calu-6	M1zPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\kcnk6UUN3ME2wMlA6PTl6IN88US=>	M2TnOHNCVkeHUh?=
BC-3	M{fWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;3NpBKSzVyPUCuNFk3PjJizszN	NIjUNY5USU6JRWK=
NCI-H2126	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1znb2lEPTB;MD6wPVc6OSEQvF2=	NHzwdmdUSU6JRWK=
NCI-H1882	MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTBwMEm4NFkh\|ryP	MljBV2FPT0WU
BB65-RCC	M17YOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXG4coxyUUN3ME2wMlExOjl2IN88US=>	NH3HZllUSU6JRWK=
DU-4475	NFrwU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33RbGlEPTB;MD6xNFQxPyEQvF2=	NV;sdpRYW0GQR1XS
NCI-H526	M3\RUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3O3OmlEPTB;MD6xNFQ1KM7:TR?=	MkjoV2FPT0WU
NEC8	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTBwMUC1NlUh\|ryP	MlfUV2FPT0WU
NCI-H1304	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTBwMUC1PVQh\|ryP	M4nPWHNCVkeHUh?=
L-540	M3rEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV2wWFJJUUN3ME2wMlExPzB6IN88US=>	NIri[YhUSU6JRWK=
NCI-SNU-16	MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nHe2lEPTB;MD6xNFc1OiEQvF2=	M4HTd3NCVkeHUh?=
HD-MY-Z	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1H4VGlEPTB;MD6xNFg2PiEQvF2=	NGDEWXVUSU6JRWK=
K-562	NXvjWmdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vsdGlEPTB;MD6xNFg2QCEQvF2=	MnHQV2FPT0WU
JAR	M2W0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTBwMUC5NlUh\|ryP	NWDBXIpVW0GQR1XS
MZ2-MEL	M{TVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTwfHNKSzVyPUCuNVExPSEQvF2=	M{LHbHNCVkeHUh?=
L-363	NYHVRolWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\ITWM2OD1yLkGxNFc6KM7:TR?=	NFW4OoZUSU6JRWK=
BV-173	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XKVWlEPTB;MD6xNVI1OyEQvF2=	M4fGZXNCVkeHUh?=
NCI-H524	MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfKN4pKSzVyPUCuNVEzPzRizszN	MXHTRW5ITVJ?
EoL-1-cell	NH;Y[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIOzVYpKSzVyPUCuNVE3PzJizszN	Mlu5V2FPT0WU
K052	NVXlZnVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfjTWM2OD1yLkGxO\|EzKM7:TR?=	NGq4[GVUSU6JRWK=
TK10	NVrvdnUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XuUGlEPTB;MD6xNVczQCEQvF2=	MoWxV2FPT0WU
KU812	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rSXGlEPTB;MD6xNlA1PCEQvF2=	NVvEbXAxW0GQR1XS
RPMI-8226	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHXemRwUUN3ME2wMlEzODV{IN88US=>	MnTLV2FPT0WU
MZ7-mel	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XwNWlEPTB;MD6xNlI{PyEQvF2=	NXnRO\|hlW0GQR1XS
SK-PN-DW	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITjeoxKSzVyPUCuNVIzQDdizszN	NULs[WdDW0GQR1XS
SR	NYPUN3VWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITifZNKSzVyPUCuNVI1PDFizszN	Mo\jV2FPT0WU
RPMI-6666	NVPMbVBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTBwMUK3OFMh\|ryP	MkfXV2FPT0WU
no-11	NIHSR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLkTWM2OD1yLkGyPFY6KM7:TR?=	NWfXXGlPW0GQR1XS
EW-3	MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn33TWM2OD1yLkGyPFk{KM7:TR?=	NVHQWldPW0GQR1XS
LAMA-84	M2LibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorOTWM2OD1yLkGzNVg4KM7:TR?=	NFLvWIJUSU6JRWK=
HT	NF7GToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3T1bGlEPTB;MD6xN\|U4PCEQvF2=	NH;aSY1USU6JRWK=
KP-N-RT-BM-1	NULMWVVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofoTWM2OD1yLkGzOlEzKM7:TR?=	NVr3b2FUW0GQR1XS
NCI-H747	NUWzSVk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXuzVZRoUUN3ME2wMlE{PyEQvF2=	NF\FSVJUSU6JRWK=
NCCIT	NXraU2w4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXNTWM2OD1yLkGzPVM6KM7:TR?=	MWTTRW5ITVJ?
MLMA	MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\uSoVKSzVyPUCuNVQyPjdizszN	MWfTRW5ITVJ?
LP-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHWTWM2OD1yLkG0NlQh\|ryP	NELsZ3RUSU6JRWK=
CAL-148	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTBwMUS0PFMh\|ryP	NYXRUYZwW0GQR1XS
GB-1	NG\KOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfqXWRpUUN3ME2wMlE1PTJ4IN88US=>	NUDXepVZW0GQR1XS
COR-L88	NXn0U453T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkO0TWM2OD1yLkG0PFAzKM7:TR?=	NX7QXJd3W0GQR1XS
NKM-1	NX\KdFlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXBTWM2OD1yLkG0PVA3KM7:TR?=	NXLnNXI{W0GQR1XS
NB5	Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jiWmlEPTB;MD6xOVQ3OiEQvF2=	NFzneVBUSU6JRWK=
SH-4	NHm3T3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnHdHhCUUN3ME2wMlE2PDZ4IN88US=>	MV7TRW5ITVJ?
EM-2	NHXvbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLURmVUUUN3ME2wMlE2PDZ5IN88US=>	MVXTRW5ITVJ?
TGBC24TKB	NUXOZWRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rlfWlEPTB;MD6xOVY2QSEQvF2=	NFPjRoFUSU6JRWK=
SCLC-21H	M4m2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYf3VotzUUN3ME2wMlE2PzB{IN88US=>	MlTwV2FPT0WU
COLO-684	NGXVdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPOe2JCUUN3ME2wMlE2PzJzIN88US=>	M4LuRnNCVkeHUh?=
KINGS-1	NIDOVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTBwMUW5NUDPxE1?	MVXTRW5ITVJ?
LS-123	NHLHXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3Db2sxUUN3ME2wMlE2QTF5IN88US=>	MYHTRW5ITVJ?
MC116	M2XIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HtN2lEPTB;MD6xOlE2QCEQvF2=	NWDxT5FpW0GQR1XS
SU-DHL-1	NFrPbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fNdmlEPTB;MD6xOlIxPiEQvF2=	M3;ufnNCVkeHUh?=
NCI-H64	NXXJd\|VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NID4SHZKSzVyPUCuNVY{PDdizszN	MV7TRW5ITVJ?
HCE-T	Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfqblVKSzVyPUCuNVY2ODRizszN	MlvBV2FPT0WU
LOXIMVI	MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17aRmlEPTB;MD6xOlk1QSEQvF2=	MWPTRW5ITVJ?
ARH-77	NGjqRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjoTWM2OD1yLkG3N\|c6KM7:TR?=	NEnLN3VUSU6JRWK=
DOHH-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjFVnNKSzVyPUCuNVc3PzJizszN	NIrZToNUSU6JRWK=
COLO-320-HSR	NUjvOo5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTmTWM2OD1yLkG4NVU1KM7:TR?=	MnrUV2FPT0WU
NB6	M4PnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\IeI1KSzVyPUCuNVg2PjZizszN	NHntc\|RUSU6JRWK=
L-428	M17aR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTBwMUi4NVMh\|ryP	MX7TRW5ITVJ?
SNB75	NYPZc2t3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XNTGlEPTB;MD6xPFgzPCEQvF2=	MVTTRW5ITVJ?
NCI-H2141	NUPNS5VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlW3TWM2OD1yLkG5NFEyKM7:TR?=	MXnTRW5ITVJ?
KARPAS-299	M1\ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTBwMUmyOFEh\|ryP	M{LWbnNCVkeHUh?=
LC4-1	NELld5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHITWM2OD1yLkG5OVAzKM7:TR?=	M4HDW3NCVkeHUh?=
UACC-257	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HCSmlEPTB;MD6xPVk1PyEQvF2=	MluyV2FPT0WU
EVSA-T	NEDyfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;wTWM2OD1yLkKwN\|EzKM7:TR?=	NEOwfWVUSU6JRWK=
JiyoyeP-2003	M33wWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWqxTHNRUUN3ME2wMlIxPDd5IN88US=>	MWHTRW5ITVJ?
NCI-H720	MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn60TWM2OD1yLkKwOVI2KM7:TR?=	NIG5PFdUSU6JRWK=
GAK	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTBwMkGxPFkh\|ryP	NEPWXVRUSU6JRWK=
HH	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnhRVNTUUN3ME2wMlIyPDB3IN88US=>	MUPTRW5ITVJ?
NCI-H1436	NV24RZEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfTPWRQUUN3ME2wMlIyPDZ2IN88US=>	M3y2U3NCVkeHUh?=
GR-ST	Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrITWM2OD1yLkKxOFg5KM7:TR?=	NYi2TI1oW0GQR1XS
BC-1	M1LVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnm4TWM2OD1yLkKyOlE3KM7:TR?=	NIe4[mZUSU6JRWK=
SIG-M5	M37pfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUG4eJF[UUN3ME2wMlIzPzJ5IN88US=>	MmXTV2FPT0WU
NCI-H345	MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYqz[4hTUUN3ME2wMlI{QDB3IN88US=>	NXTCT5o{W0GQR1XS
OPM-2	M2nu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkD3TWM2OD1yLkKzPFgzKM7:TR?=	NH3rW4RUSU6JRWK=
LB1047-RCC	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDu[pdEUUN3ME2wMlI1PDFizszN	NUXmSGNYW0GQR1XS
CTB-1	M1zDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrodpVKSzVyPUCuNlQ1QTNizszN	NXTafFVTW0GQR1XS
A3-KAW	MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTBwMkWzOFEh\|ryP	NUm5PJU3W0GQR1XS
SF126	M1r1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MortTWM2OD1yLkK1N\|g{KM7:TR?=	MW\TRW5ITVJ?
KARPAS-422	NX33V4Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXyN5hIUUN3ME2wMlI2PDN3IN88US=>	M365dXNCVkeHUh?=
MEG-01	NIjXOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIW4VJZKSzVyPUCuNlU3PzNizszN	M3nufnNCVkeHUh?=
NCI-H209	NHXvWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXS2TZBIUUN3ME2wMlI3Ozd2IN88US=>	MX7TRW5ITVJ?
SBC-1	NG[3OIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLFTWM2OD1yLkK2OUDPxE1?	Ml7zV2FPT0WU
K5	M1frdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\XV2lEPTB;MD6yOlk5PCEQvF2=	M1nWUnNCVkeHUh?=
QIMR-WIL	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1SyeWlEPTB;MD6yO\|E2PSEQvF2=	NEfTNJVUSU6JRWK=
NMC-G1	NFi2NXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PqNmlEPTB;MD6yPFIyPyEQvF2=	MnO0V2FPT0WU
IST-MES1	MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHjbXVKSzVyPUCuNlkzOzhizszN	M4j1fXNCVkeHUh?=
SW684	M1rPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnQTWM2OD1yLkOwNFQ4KM7:TR?=	M1\YNHNCVkeHUh?=
MV-4-11	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjmTWM2OD1yLkOwO\|g5KM7:TR?=	MXzTRW5ITVJ?
LAN-6	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rJbWlEPTB;MD6zNVU4OiEQvF2=	Mmr1V2FPT0WU
RH-1	NFPWfXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVztSoQ3UUN3ME2wMlMyQDdzIN88US=>	NV\yVFdqW0GQR1XS
CP66-MEL	M3fuN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfpTWM2OD1yLkOxPFc5KM7:TR?=	NX23UZV5W0GQR1XS
EC-GI-10	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fCc2lEPTB;MD6zNlk5PyEQvF2=	NEfGTIpUSU6JRWK=
GDM-1	NFjkbopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLKTWM2OD1yLkOzNFU6KM7:TR?=	MUfTRW5ITVJ?
IST-SL1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTBwM{S5NVQh\|ryP	M2[0OnNCVkeHUh?=
KMOE-2	M2jKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTBwM{WxO\|Uh\|ryP	M1naXnNCVkeHUh?=
OS-RC-2	Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rQeGlEPTB;MD6zOVU1PCEQvF2=	MknqV2FPT0WU
HDLM-2	M2\ZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTBwM{e4NVQh\|ryP	NF;j[ZNUSU6JRWK=
DSH1	NVuxR3JWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXyT3dKSzVyPUCuN\|g3OzFizszN	NI\wcoJUSU6JRWK=
LS-1034	M1\XSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnwfYlSUUN3ME2wMlM5QTV2IN88US=>	NVnMSWJDW0GQR1XS
LB373-MEL-D	NGjjeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVflV5JwUUN3ME2wMlM6OTl5IN88US=>	MmXYV2FPT0WU
GOTO	M3XNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\K[3N5UUN3ME2wMlQzOTF6IN88US=>	M1H0fXNCVkeHUh?=
MRK-nu-1	NXPOV\|EyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfSTWM2OD1yLkSyNlA2KM7:TR?=	NFO4NWlUSU6JRWK=
SK-MM-2	Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXzXWduUUN3ME2wMlQ{PDR{IN88US=>	Mn[1V2FPT0WU
BOKU	NGTjWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4G2PGlEPTB;MD60N\|c6OiEQvF2=	MXHTRW5ITVJ?
NOMO-1	NIroVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjDbXVuUUN3ME2wMlQ{QDZizszN	M33RTnNCVkeHUh?=
J-RT3-T3-5	NXP0RWlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;td2lEPTB;MD60OFg4QCEQvF2=	M2P1SnNCVkeHUh?=
COLO-668	NVPCRmtzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPOTWM2OD1yLkS1OlY5KM7:TR?=	MYXTRW5ITVJ?
SF539	NEPpfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTBwNEi2PFQh\|ryP	NX3RVJdnW0GQR1XS
LB2518-MEL	M1rWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn72TWM2OD1yLkS5O\|A{KM7:TR?=	NYXYNItkW0GQR1XS
TE-441-T	NX7oTo12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTBwNUCxNkDPxE1?	M2XiU3NCVkeHUh?=
MDA-MB-134-VI	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV:yVIpKUUN3ME2wMlUxQTJzIN88US=>	NXXzUIxFW0GQR1XS
SCC-3	NVHrV3VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIC0eoVKSzVyPUCuOVE5PzNizszN	MkL2V2FPT0WU
KLE	NY[5bHFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XJW2lEPTB;MD61NlE4OSEQvF2=	NGH1Om9USU6JRWK=
LB2241-RCC	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPuW3lKSzVyPUCuOVI2OjVizszN	MWXTRW5ITVJ?
NCI-H1417	NI\5eI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37DR2lEPTB;MD61N\|Q{PSEQvF2=	M12xd3NCVkeHUh?=
NCI-H2081	MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDteHpKSzVyPUCuOVg3OTFizszN	MVTTRW5ITVJ?
NCI-H1522	NWPGRZA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjKcW52UUN3ME2wMlU6Ozh\|IN88US=>	M4XsOnNCVkeHUh?=
NCI-H889	NFyzcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfnW\|ZKSzVyPUCuOVk5PDRizszN	MoLqV2FPT0WU
CGTH-W-1	M4TJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDzPJNKSzVyPUCuOlA4PTVizszN	NUfiVYJRW0GQR1XS
EB-3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLmTWM2OD1yLk[xNVU{KM7:TR?=	NF31U\|VUSU6JRWK=
D-336MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTBwNkG3PVEh\|ryP	MV3TRW5ITVJ?
LC-1F	NIjySllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvRVI9sUUN3ME2wMlYzPTl{IN88US=>	M2jq[3NCVkeHUh?=
MHH-NB-11	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\PbWlEPTB;MD62N\|gxOSEQvF2=	MkPVV2FPT0WU
SK-N-FI	NXzDSnVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3TTWM2OD1yLk[zPVEh\|ryP	MV3TRW5ITVJ?
NCI-H69	NXXOe41sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHobHF{UUN3ME2wMlY1QDd7IN88US=>	NXnPRZp1W0GQR1XS
SCH	M1LFR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTXeJdxUUN3ME2wMlY3ODJ\|IN88US=>	M{XOSXNCVkeHUh?=
LS-513	M3LpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHI[2QxUUN3ME2wMlY4OjV7IN88US=>	MYDTRW5ITVJ?
CP67-MEL	NI\hXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTBwNke1PVYh\|ryP	NILJTI5USU6JRWK=
GCIY	NGDWbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnme456UUN3ME2wMlcxOzZ\|IN88US=>	NYXGXYFCW0GQR1XS
SHP-77	M2HOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XP[GlEPTB;MD63NFc{PCEQvF2=	NFfETHZUSU6JRWK=
EHEB	MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHxTWM2OD1yLkexPFU1KM7:TR?=	NYW1cXF[W0GQR1XS
D-247MG	NGPvOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVP1UXFKUUN3ME2wMlc{OjN{IN88US=>	M4DnTXNCVkeHUh?=
Raji	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;OWHpCUUN3ME2wMlc1QTh7IN88US=>	NHz3XnJUSU6JRWK=
MPP-89	MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHu4V41KSzVyPUCuO\|U6PzhizszN	M4S5RXNCVkeHUh?=
EKVX	NFfjVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTBwN{mwO\|Mh\|ryP	MUDTRW5ITVJ?
HCC2218	NGT1dXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTBTWM2OD1yLke5NVMyKM7:TR?=	NYCzflhSW0GQR1XS
KNS-81-FD	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTBwOEGwNVEh\|ryP	NU\4Z2ZiW0GQR1XS
HCC2157	NV7qPGlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTQTWM2OD1yLki0PVUyKM7:TR?=	NGfn[VhUSU6JRWK=
BT-474	NUTJfodlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vVZ2lEPTB;MD64PFg2PCEQvF2=	Mo\yV2FPT0WU
NCI-H748	Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jvPGlEPTB;MD65NVIh\|ryP	NHP5ZZlUSU6JRWK=
EW-24	NF;xOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTKTWM2OD1yLkmyNFAzKM7:TR?=	NHeyS2dUSU6JRWK=
D-263MG	NGTBelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1H1T2lEPTB;MD65OFUyOiEQvF2=	MX\TRW5ITVJ?
OMC-1	NWDkdIVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjqbnhKSzVyPUCuPVY{PzNizszN	NFfNNZZUSU6JRWK=
NCI-H2196	MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7Cem1KSzVyPUCuPVc4PzdizszN	NWXYWZozW0GQR1XS
HAL-01	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPxW2o1UUN3ME2wMlk6QDd{IN88US=>	Mnv6V2FPT0WU
NCI-H2107	NVLmSphiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPwbGV3UUN3ME2xMlAyQDV2IN88US=>	M3u3cnNCVkeHUh?=
LB996-RCC	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjQZYdqUUN3ME2xMlA5ODVzIN88US=>	NGXnRYdUSU6JRWK=
NCI-H1395	NGHwSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnhTotqUUN3ME2xMlExPjdizszN	NGHvUWdUSU6JRWK=
CHP-126	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NET6endKSzVyPUGuNVYyQTlizszN	NYO2fmVqW0GQR1XS
NB69	MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XrVGlEPTB;MT6yOlE1QCEQvF2=	MXvTRW5ITVJ?
CAS-1	MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLMUVJRUUN3ME2xMlM1OjNzIN88US=>	NF;jO5dUSU6JRWK=
JVM-3	MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTMXVJjUUN3ME2xMlQ4QDV3IN88US=>	NWPOeYNmW0GQR1XS
DMS-153	MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY[5[o9FUUN3ME2xMlU4Pjd2IN88US=>	Mnz0V2FPT0WU
SK-MEL-2	MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;J[2lEPTB;MT63NVc5QSEQvF2=	M3jWVnNCVkeHUh?=
NCI-H1155	MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7OSJNKSzVyPUGuO\|M3PzZizszN	M{DGVXNCVkeHUh?=
NCI-H1092	NWnFN\|I1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTFwN{[xPFIh\|ryP	MlHMV2FPT0WU
LU-165	NEPJS5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXaTnpVUUN3ME2xMlg3PDd4IN88US=>	MoDvV2FPT0WU
HL-60	M334fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDSWWJMUUN3ME2xMlk6QTB6IN88US=>	NEHDTXFUSU6JRWK=
REH	M1rXXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPa[W9KSzVyPUKuNFA2QDJizszN	NWnpfWVLW0GQR1XS
JVM-2	MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\GTWM2OD1{LkC2NVM2KM7:TR?=	MlrwV2FPT0WU
MN-60	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTTUnN1UUN3ME2yMlE4OzB6IN88US=>	NGj5OXlUSU6JRWK=
SCC-15	M3;scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfXS5RqUUN3ME2yMlIxOjdizszN	Mle3V2FPT0WU
SNU-C1	NYnFd\|NVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHicmFKSzVyPUKuNlE{PDNizszN	NV;xRXplW0GQR1XS
SK-MEL-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG[5V25KSzVyPUKuN\|IxPDdizszN	MX3TRW5ITVJ?
TGW	NG\X[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfhe4tlUUN3ME2yMlM2ODJ5IN88US=>	M3XEVnNCVkeHUh?=
CA46	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TGU2lEPTB;Mj63OVk3PyEQvF2=	Ml7HV2FPT0WU
NCI-H23	NWm1TIVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGWzXVJKSzVyPUKuPFA4QTFizszN	MorTV2FPT0WU
MMAC-SF	NYXZU2JyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTiZXhMUUN3ME2yMlg3PjJ6IN88US=>	M3vRfHNCVkeHUh?=
NCI-H2171	NXvZb\|ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzyfY11UUN3ME2zMlA{PDR6IN88US=>	NIrXOFRUSU6JRWK=
A704	MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3[xb2lEPTB;Mz6xOFE6PCEQvF2=	MVzTRW5ITVJ?
DB	M{fuc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3L3W2lEPTB;Mz6yOVU4PiEQvF2=	MWTTRW5ITVJ?
NCI-H719	M4XQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTNwM{CzPFQh\|ryP	NHfWTnJUSU6JRWK=
MC-CAR	MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;ZcI5KSzVyPUOuOVQ5OTdizszN	MoXEV2FPT0WU
SIMA	NGrvTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfJTWM2OD1\|LkW4OFE3KM7:TR?=	Mn;KV2FPT0WU
SW872	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojxTWM2OD1\|Lke4NVAyKM7:TR?=	NH7SNGpUSU6JRWK=
HCC1187	NYXmfW1ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXGTWM2OD1\|Lke4N\|E2KM7:TR?=	NYfCSoxXW0GQR1XS
EW-13	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrUTWM2OD1\|LkizOFE4KM7:TR?=	NFmwZYlUSU6JRWK=
NCI-SNU-1	M4Wybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnFXHY{UUN3ME20MlIyQTl7IN88US=>	MXXTRW5ITVJ?
NCI-H226	MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTvZZpKSzVyPUSuN\|M3ODZizszN	M320S3NCVkeHUh?=
RPMI-8866	MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojSTWM2OD12LkO2NFI6KM7:TR?=	NFrKOYlUSU6JRWK=
OCI-AML2	M{fDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTRwNUWyN{DPxE1?	MmPqV2FPT0WU
LU-65	NIXDe\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHKTWM2OD12LkmzNFM{KM7:TR?=	NW\XcGkyW0GQR1XS
SK-N-DZ	MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEWyRpNKSzVyPUWuOlM1PjVizszN	NVzYTlBMW0GQR1XS
NB14	NUXNTXVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILGNGhKSzVyPUWuPVcyOzVizszN	NE\jPZpUSU6JRWK=
COLO-829	NFjKVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTZwM{OzOVkh\|ryP	NFjxPXFUSU6JRWK=
MHH-CALL-2	NYDKOYNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPXXIpKSzVyPU[uOVE2ODhizszN	MkLNV2FPT0WU
NCI-H1770	NI\Qc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPGTWM2OD14Lk[2PVA1KM7:TR?=	M37CTnNCVkeHUh?=
ECC4	NUW3Z2FRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTZwOEKxO\|kh\|ryP	Ml\OV2FPT0WU
A498	MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vtSGlEPTB;Nj64O\|E6OiEQvF2=	MoTtV2FPT0WU
DMS-79	NHPXUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfUTWM2OD15LkC0OVEzKM7:TR?=	NIn0VWJUSU6JRWK=
P30-OHK	NUO1fZV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzRd3BKSzVyPUeuNlE6ODZizszN	NYfwN3Q2W0GQR1XS
D-502MG	MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnS5TWM2OD15Lkm4N\|Yh\|ryP	NHjvZ3FUSU6JRWK=
RCC10RGB	Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\DNJlKSzVyPUiuNFYzQCEQvF2=	Mln5V2FPT0WU
U-698-M	Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnToTWM2OD16LkK5NlI3KM7:TR?=	NWDkXlJrW0GQR1XS
BB49-HNC	M4fHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rJS2lEPTB;OT60NlI3PSEQvF2=	MmfkV2FPT0WU
ES1	NHnTR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTlwNki5OVYh\|ryP	MU\TRW5ITVJ?
MFM-223	NWDPTZNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTFyLkm5Nlch\|ryP	MnHZV2FPT0WU
C2BBe1	M2Djc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;GTWM2OD1zMT6zOVI{KM7:TR?=	MV;TRW5ITVJ?
EB2	MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\uZoxKSzVyPUGyMlY5QDFizszN	MYLTRW5ITVJ?
C8166	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nK[GlEPTB;MUOuPFMxOyEQvF2=	MWnTRW5ITVJ?
ES3	MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPDPFNKSzVyPUGzMlk6PzdizszN	M{\E[HNCVkeHUh?=
NCI-H1650	M3y2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPHU2RzUUN3ME2xOk4{PzZ3IN88US=>	NGPxe4NUSU6JRWK=
Mo-T	NHjJS\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLhfYd4UUN3ME2xO{41ODJ7IN88US=>	M{Gx[HNCVkeHUh?=
NB7	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLyTWM2OD1zNz63OFY4KM7:TR?=	NHHWbYtUSU6JRWK=
ES7	MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrJXoZvUUN3ME2xPU42PTB5IN88US=>	MkjlV2FPT0WU
ES5	MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX35NHliUUN3ME2yNU44PjdzIN88US=>	NFPXSG5USU6JRWK=
MSTO-211H	MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHCVpBKSzVyPUKxMlg5PThizszN	M3rWe3NCVkeHUh?=
U-87-MG	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLiTWM2OD1{NT6xPVY3KM7:TR?=	MYLTRW5ITVJ?
THP-1	M3j6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfmXpNKSzVyPUK5MlczODFizszN	M{PleXNCVkeHUh?=
NB10	M3rzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTNyLkK2PVQh\|ryP	MkLXV2FPT0WU
NH-12	NELyXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7PTWM2OD1\|Mz6yNFE4KM7:TR?=	NGP1VHNUSU6JRWK=
COLO-824	MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoWxTWM2OD1\|ND6xNFA3KM7:TR?=	M1v6WXNCVkeHUh?=
SKM-1	NWf4SXJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrPTlZKSzVyPUO3Mlg1OjJizszN	NX31XW05W0GQR1XS
NCI-H1838	NEDPWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\DTWM2OD1\|OD6zO\|k4KM7:TR?=	NXTIOY1iW0GQR1XS
RL	M2Hmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHv3eppKSzVyPUO5MlI1PzdizszN	NEDXXVFUSU6JRWK=
COLO-800	NHmybZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnaTWM2OD12MD6wO\|c{KM7:TR?=	MXzTRW5ITVJ?
KG-1	M1PaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTRyLki5OVUh\|ryP	NUDUT3ZsW0GQR1XS
TUR	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTRzLk[zPVkh\|ryP	NVHqUVBxW0GQR1XS
LNCaP-Clone-FGC	MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTRzLkmwNVch\|ryP	M{jEUHNCVkeHUh?=
NCI-H322M	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTR{LkW5PFQh\|ryP	MUfTRW5ITVJ?
LNCaP	NYnNS4JKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\uTWM2OD17MT6zJI5O	M2HzeFI2PTB3MUe0
C4-2	Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjwVYVKSzVyPUigcm0>	NYTJeoQ2OjV3MEWxO\|Q>
JURKAT	NXHDVFI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnzzNlQhcA>?		NYDyUHEyUUN3ME20NVYvPjZibl2=	NH3HR\|gzPDVzOUm5OS=>
MOLT-4	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnLqNlQhcA>?		MVfJR\|UxRTJ6NUOuOUBvVQ>?	M3nYdVI1PTF7OUm1
REH	MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnHqNlQhcA>?		MYjJR\|UxRTJ6Nz62PEBvVQ>?	MVeyOFUyQTl7NR?=
NALM-6	M1u2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWnNVpQ{OjRiaB?=		MWHJR\|UxRTN2M{OwJI5O	MUCyOFUyQTl7NR?=
RS 4;11	NWDlT5gyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXqyOEBp		NYjBXJVZUUN3ME21NVkvODVibl2=	M1XFW\|I1PTF7OUm1
697	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlXUNlQhcA>?		Mn7KTWM2OD1{MUC3MlEhdk1?	MX2yOFUyQTl7NR?=
SIL-ALL	NGXwWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MknmNlQhcA>?		Mof2TWM2OD1zOUmuO\|chdk1?	NF\N[XEzPDVzOUm5OS=>
CEM	NWGxbplKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVPreFhDOjRiaB?=		NI\xfYxKSzVyPUWyMlE5KG6P	NYr0bGJXOjR3MUm5PVU>
P12	NUHR[5lmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoPZNlQhcA>?		MnnQTWM2OD1\|OT6yO{BvVQ>?	MmXZNlQ2OTl7OUW=
NALM-16	NUnXVm15T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUXmNXRrOjRiaB?=		M1jxS2lEPTB;OU[uNlghdk1?	NWPKZoc{OjR3MUm5PVU>
JURKAT	M3nMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnO1OFghcA>?		Mn7OTWM2OD1zND64OEBvVQ>?	NFLhfGMzPDVzOUm5OS=>
MOLT-4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUTPUoFsPDhiaB?=		MXjJR\|UxRTJ4Lk[gcm0>	Mn7vNlQ2OTl7OUW=
REH	NGfpfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVW0PEBp		MUXJR\|UxRTR2LkexJI5O	M4HsXlI1PTF7OUm1
NALM-6	NVez[3RqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUW0PEBp		NV\MbnBwUUN3ME2yN{4zPiCwTR?=	M{TxOFI1PTF7OUm1
RS 4;11	NVOz[3BDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4SyUlQ5KGh?		MnroTWM2OD1zNkSuNlghdk1?	MYqyOFUyQTl7NR?=
697	NXK0cWg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mo\YOFghcA>?		MnHvTWM2OD1\|MEWuN{BvVQ>?	MWqyOFUyQTl7NR?=
SIL-ALL	NFP6UFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX3EZmZOPDhiaB?=		MYfJR\|UxRTd2Lk[yJI5O	M1jnW\|I1PTF7OUm1
CEM	NGjCWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHf1bWw1QCCq		MkTMTWM2OD1{ND61OUBvVQ>?	M1L5d\|I1PTF7OUm1
P12	NYLXNIxzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH:xVmE1QCCq		MYnJR\|UxRTF6LkS2JI5O	MlH2NlQ2OTl7OUW=
NALM-16	NYHCfoFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml:5OFghcA>?		MYTJR\|UxRTZ\|LkK0JI5O	NIfieJIzPDVzOUm5OS=>
JURKAT	NVr5OWxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mlj4O\|IhcA>?		MVnJR\|UxRTNwNkWgcm0>	M4n4eFI1PTF7OUm1
MOLT-4	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MW[3NkBp		NWqyepRJUUN3ME23MlM6KG6P	M1jLdlI1PTF7OUm1
REH	NXzUS3ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX7od\|FpPzJiaB?=		M1z5WWlEPTB;MU[uNFEhdk1?	MXWyOFUyQTl7NR?=
NALM-6	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYO4UZlmPzJiaB?=		M1HzZ2lEPTB;MT63PEBvVQ>?	NIPyXYIzPDVzOUm5OS=>
RS 4;11	MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXfDdYlnPzJiaB?=		M3TpNWlEPTB;ND6zPEBvVQ>?	NHnFcGIzPDVzOUm5OS=>
697	NWfRTlhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWO3NkBp		NYeyXlVxUUN3ME23OE4zQCCwTR?=	NUL4S5pDOjR3MUm5PVU>
SIL-ALL	MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NInwO5Q4OiCq		M{fYPGlEPTB;Nz6yJI5O	NYTKVYh7OjR3MUm5PVU>
CEM	M3;TU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M17KT\|czKGh?		M{GyOmlEPTB;NT60NkBvVQ>?	NIroNpUzPDVzOUm5OS=>
P12	Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4HPc\|czKGh?		NUDXZZRuUUN3ME22MlM4KG6P	NUHsU4lvOjR3MUm5PVU>
NALM-16	Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2\Pd\|czKGh?		NV\tPFFLUUN3ME23O{44OyCwTR?=	MnzDNlQ2OTl7OUW=
Y79	M{PFZ2Fxd3C2b4Ppd{BCe3OjeR?=	M4q4eVEuPTBibl2=	Mo[0NVIwOjRiaB?=	MYrEUXNQ	MV\pcoR2[2WmIHHwc5B1d3OrczD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nliSGS=	NV7pbnVsOjR\|Nk[2OlU>
WER-Rb-1	M2HvSWFxd3C2b4Ppd{BCe3OjeR?=	NV:3dI9tOS13MDDuUS=>	MXmxNk8zPCCq	M{OzVmROW09?	MU\pcoR2[2WmIHHwc5B1d3OrczD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nliSGS=	NFfBOoUzPDN4Nk[2OS=>
G7	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XUTGlEPTB;Mz6zJI5O	NYXRNlBSOjR{MES3N\|M>
G166	NGT1dYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfITWM2OD15LkCgcm0>	M33vOVI1OjB2N{Oz
CB660	NHLMXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTZwNDDuUS=>	MVGyOFIxPDd\|Mx?=
CB1117	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjt[mdUUUN3ME2xOU43KG6P	NELiUlkzPDJyNEezNy=>
KB-3-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;rOHVKSzVyPUGuOFghyrFiMD61N{BvVQ>?	M4\Q[\|I{QTZ{NES1
KB-8-5-11	MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2X5NmlEPTB;NT6wNUDDuSB{LkCxJI5O	NV;3[mg1OjN7NkK0OFU>
KB-C-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHPc45pUUN3ME2xOk44PiEEsTC0MlUyKG6P	NH3EV5ozOzl4MkS0OS=>
KB-V-1	NXLlUXI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkeyTWM2OD1{OEGuNlQhyrFiM{GuOVchdk1?	NIL6SVEzOzl4MkS0OS=>
OVCAR-8	NGC3UXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTdwMUmgxtEhOy54MDDuUS=>	NELhZ3gzOzl4MkS0OS=>
NCI-ADR-RES	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTF{N{OuN\|AhyrFiMUmxMlIxKG6P	NEHoRoczOzl4MkS0OS=>
MCF7	M4DHTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTyTnJvUUN3ME21MlEyKMLzIEGuOFchdk1?	M4\icFI{QTZ{NES1
MCF7-FLV1000	NIDJTWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfMTWM2OD1\|OUOuNVghyrFiN{SuPFMhdk1?	NFTNSFQzOzl4MkS0OS=>
S1	NHezVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTJ2LkOwJOKyKDRwN{Wgcm0>	M2LMd\|I{QTZ{NES1
S1-M1-80	NHLxb\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzrO3hKSzVyPUK2NU4xPiEEsTC0PE4zPSCwTR?=	MlvINlM6PjJ2NEW=
CORL-23/P	NE[5Z2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrIOI5VUUN3ME20MlM5KMLzIEGuNlUhdk1?	NFnVXJozOzl4MkS0OS=>
CORL-23/R	NUfBOlNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3VTWM2OD13LkG2JOKyKDFwOEOgcm0>	NHvSdWEzOzl4MkS0OS=>
NIH3T3	NYPrfpJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTRyLk[wJOKyKDRwOUegcm0>	NGjXbpMzOzl4MkS0OS=>
NIH3T3-G185	MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXn1fldnUUN3ME2yOFE{NjRyINMxJFQzOy54NjDuUS=>	Ml[wNlM6PjJ2NEW=
pcDNA-HEK293	NEPNbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTJwN{WgxtEhOC54NzDuUS=>	M1PifVI{QTZ{NES1
MDR19-HEK293	NH7WWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jRRmlEPTB;OEWuOVAhyrFiMUOuOlchdk1?	MYOyN\|k3OjR2NR?=
R482-HEK293	NIGzT4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGmwRlJKSzVyPUK1Mlk4KMLzIESuPVUhdk1?	NFfJZY0zOzl4MkS0OS=>
MRP1-HEK293	NGD6c2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTJwOUmgxtEhOS52OTDuUS=>	MVyyN\|k3OjR2NR?=
SF188	MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\HNVAuOTByIH7N	NYH0eZdWOjRvOU[gbC=>	MUnEUXNQ	NVfhUHVlcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiY3;uZ4VvfHKjdHnvck0h\GWyZXTlcpQhdWGwbnXy	M3nqeFI{QDh5NkS1
T98G	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX21dYs6OTBvMUCwJI5O	MXqyOE06PiCq	MV\EUXNQ	M4PFWYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHPvcoNmdnS{YYTpc44uKGSncHXk[Y51KG2jbn7ldi=>	MoTQNlM5QDd4NEW=
DU145	M336cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXXEUXNQ	MUHJR\|Ux6oj:NkCgcm0>	NGXMcWYzOzh6NESyPC=>
LNCaP	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3vjd2ROW09?	M1;MTGlEPTEkiMy3OUBvVQ>?	NYT3fmR5OjN6OES0Nlg>
PC3	M4K3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEPkdFNFVVOR	NFPrZ4VKSzVy4pk8NVc2KG6P	NYjTeZZNOjN6OES0Nlg>
RT4	MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DRXWlEPTB;MkeuNlEhdk1?	NFv2SFEzOzd7Mk[zPS=>
5637	NWjI[3ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDHTINHUUN3ME20OU41PyCwTR?=	MVGyN\|c6OjZ\|OR?=
T24	MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TXcGlEPTB;N{muNVIhdk1?	MUWyN\|c6OjZ\|OR?=
MCF7	Mm[xSpVv[3Srb36gRZN{[Xl?	NYr1N2FmOTByIH7N	MoG0NUBp	MXjEUXNQ	M37a[JJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZtMgS5Jm[jFuwrDT[4syNMLiUIOyMOKhW2W{cHnuZVMtKGGwZNMgW4l{eDJ?	MljGNlM4PzB{NES=
KB-V1	NULzRYk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDQPXVKSzVyPUOuPVIh\|ryP	MkHvNlM2QTNzOU[=
Hec50co	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETiVGNKSzVyPUWgcm0>	MVOyN\|E1PjZ6Nx?=
MDA-MB-468	NV3DNXFpSXCxcITvd4l{KEG\|c3H5	NF7RUWkyNzVxMUCgcm0>	NUDpXod1OjRxNEivO\|IhcA>?	NHrwUppFVVOR	NH25UHNqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NELjRXUzOzF2NEK5OC=>
MCF10A	NHf1XYxCeG:ydH;zbZMhSXO\|YYm=	M33XOFEwPS9zMDDuUS=>	MlruNlQwPDhxN{KgbC=>	M2XYfGROW09?	MoLybY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NH7VRWYzOzF2NEK5OC=>
Huh-7	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\SS4NGOS9zMD:xNFAwOTByMDDuUS=>	MkD0OFghcA>?		NYfkUWVN\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCmb4PlMYRmeGWwZHXueIx6	MW[yNlc1PTV6Nx?=
Daoy	M3njV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIntfoUyNjh5NT2yOFAhdk1?	M3O1VlczKGh?	NXHOfYZjTE2VTx?=	M1LxfGlEPTB;NTDuUS=>	M4nuTFIzOzlyMke5
ONS-76	MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvrNU45PzVvMkSwJI5O	NYDLOXNWPzJiaB?=	NH;lR5NFVVOR	MmXkTWM2OD15LkWgcm0>	NYfwOXJKOjJ\|OUCyO\|k>
SUM 149	M1XKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDYcGkxNTFyMDDuUS=>	NXrGRZprPzJiaB?=		MWnpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	NGPKfmEzOjNyOUmzPS=>
MDA-MB-231	NUPiN\|JOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVj2SodnOC1zMECgcm0>	NGDCbJg4OiCq		NVvucVF[cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	NXexXZVzOjJ\|MEm5N\|k>
HR5	MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXTTYdbOC1zMECgcm0>	NYHLTWlJPzJiaB?=		NHvwZ3RqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI>	MlTGNlI{ODl7M{m=
BT-474-M1	Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrkUIdyOC1zMECgcm0>	NHy4V3c4OiCq		NV7zR4lkcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	NI\wZZMzOjNyOUmzPS=>
AU565	MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV[wMVExOCCwTR?=	M4PpOlczKGh?		M{PP[olvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	NIr6OmgzOjNyOUmzPS=>
T47D	M2HwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jTcFAuOTByIH7N	NUfwSG5KPzJiaB?=		NXm2VGdtcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	M13qOVIzOzB7OUO5
MCF7	M2\CT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXywMVExOCCwTR?=	NXjvVHp6PzJiaB?=		NYHONJVNcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	MWGyNlMxQTl\|OR?=
HCT116p53(+/+)	NYmwfWk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV2xNE0yODByIH7N	MYeyOE81QCCq		MV3pcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gZ49ueGyndHXsfUBifCB{NTDuUS=>	NWLtWWZsOjJ{NkKxO\|E>
HCT116p53(-/-)	NULQNVZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYixNE0yODByIH7N	NVzMS5ZsOjRxNEigbC=>		NIHwV\|JqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h[2:vcHzleIVtgSCjdDCyOUBvVQ>?	MYiyNlI3OjF5MR?=
HeLa	M{K5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LHSlExNTFyMDDuUS=>	MlvpOFghcA>?	MV\EUXNQ	MUnJR\|UxRTV{Lkmgcm0>	NVjMc2t[OjJyOECyN\|U>
HeLa	MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHW0do0yOC1zMECgcm0>	MWO3NkBp	MVjEUXNQ	NEDBUXhKSzVyPUWwMlUhdk1?	NUmydIpmOjJyOECyN\|U>
GBC	NEm3[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXW3NkBp		NHvkbJdKSzVyPUG0Mlc5KG6P	NILjXYkzOTl4NUezPS=>
GB-CL-1	NVTpVpduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4\X[\|czKGh?		Mn\UTWM2OD13LkKyJI5O	NWLhXoczOjF7NkW3N\|k>
Mz-ChA-2	NX3ET4pST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGTZR2I4OiCq		NE\uZWxKSzVyPUOuN\|Ehdk1?	MYCyNVk3PTd\|OR?=
TGBC1-TKB	M{L5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4rBNlE1PCCq		NFnLOnJKSzVyPU[uO\|Ihdk1?	MYGyNVk3PTd\|OR?=
Wittier	NUK1b2p3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoDZO\|IhcA>?		M{eySmlEPTB;Mz6yOkBvVQ>?	MknMNlE6PjV5M{m=
H-1	M1jsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV2xSFc{PzJiaB?=		NV20TGxzUUN3ME25MlU1KG6P	NXPPTYNuOjF7NkW3N\|k>
HuH-28	MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXOwPFRzPzJiaB?=		MV;JR\|UxRTFzLkG5JI5O	NV:2[IpyOjF7NkW3N\|k>
NEC	Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUfST4JGPzJiaB?=		M2PaRWlEPTB;OT65PEBvVQ>?	M3vXe\|IyQTZ3N{O5
REB	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX:3NkBp		MkL5TWM2OD1zMz61NUBvVQ>?	NILKcHUzOTl4NUezPS=>
CC-LP-1	NHTQe5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmDWO\|IhcA>?		MV7JR\|UxRTVwOESgcm0>	M4j6WFIyQTZ3N{O5
CC-SW-1	NHy1cVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV:4coFpPzJiaB?=		MnvDTWM2OD17LkW1JI5O	NFrubmQzOTl4NUezPS=>
EGI-1	M3SzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFi5TZU4OiCq		M1nYXWlEPTB;MUCuO\|Ihdk1?	MXuyNVk3PTd\|OR?=
Sk-ChA-1	MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2i2[VczKGh?		MlzRTWM2OD1zNz6yJI5O	NYH1VplpOjF7NkW3N\|k>
TFK-1	M4jlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVy3NkBp		NXTiZ4J[UUN3ME2xN{41PSCwTR?=	NUHEeJplOjF7NkW3N\|k>
786-O	NIn3eJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fLV\|UuQDBibl2=	MXu5OkBp	NITBd4RJS2x?	Mn;Sd5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P	NHrGNlMzOTZ2MkO3OC=>
A498	NYfvUoJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXPOU05OCCwTR?=	M{PsbFk3KGh?	M3fxeGhEdA>?	NYS2VnBWe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	MUKyNVY1OjN5NB?=
ACHN	NILYdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{GyPFUuQDBibl2=	MUC5OkBp	Mn[zTGNt	MlLPd5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P	M1\iRVIyPjR{M{e0
Caki-1	M2rQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorrOU05OCCwTR?=	M1r3S\|k3KGh?	M3fs[WhEdA>?	NUO5dXEze3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	M{fBXFIyPjR{M{e0
SN12C	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nvbVUuQDBibl2=	M3LWV\|k3KGh?	NVu4PHJIUEOu	NEHCRVV{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2=	Mo\3NlE3PDJ\|N{S=
HMC-1.1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nVZlEuOTByMDDuUS=>	MlqzO\|IhcA>?		MlfLbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5m	NGTWN40zOTJ2MkG4PS=>
HMC-1.2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXyxMVExODBibl2=	NHO2bnA4OiCq		NH3S[GNqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmV?	Mn[yNlEzPDJzOEm=
C2	NHfR[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH64coUyNTFyMECgcm0>	NETLV\|M4OiCq		MnTIbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5m	MlfXNlEzPDJzOEm=
CHP-212	Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETVfFQyNTF{NTDuUS=>	MkDuNlQuOTJyIHi=		M1;DXIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	NXTGcpRkOjFzNkmyOFI>
IMR-32	M33KUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUWxMVEzPSCwTR?=	MkexNlQuOTJyIHi=		NFzq[mlqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	MU[yNVE3QTJ2Mh?=
Kelly	NYHOR4FyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYexMVEzPSCwTR?=	MYmyOE0yOjBiaB?=		Mn7zbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	NEjQemgzOTF4OUK0Ni=>
SH-EP	MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnz2NU0yOjVibl2=	Mnj1NlQuOTJyIHi=		NITReIRqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	M2TOO\|IyOTZ7MkSy
SH-SY5Y	NUfUbohnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3DUo4yNTF{NTDuUS=>	MkPTNlQuOTJyIHi=		MYLpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	MUGyNVE3QTJ2Mh?=
SK-N-AS	MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;mNU0yOjVibl2=	NYXSb4U{OjRvMUKwJIg>		MnvSbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	MY[yNVE3QTJ2Mh?=
SK-N-BE	NWHq[FBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XwTVEuOTJ3IH7N	NETZZlkzPC1zMkCgbC=>		M1i2WIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	NFPvbVgzOTF4OUK0Ni=>
KG1	NVPW[mVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XmOlEwOTBxMUCwJI5O	M3LOT\|czKGh?	NGDMNFVFVVOR	MYLpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	MoHENVk1PTh\|NUi=
U937	Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfUNU8yOC9zMECgcm0>	MoPaO\|IhcA>?	NV\xbo17TE2VTx?=	NEPmdItqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	NXHsc4ZXOTl2NUizOVg>
CAL62	M3K0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;WNE4yNTFyMDDuUS=>	Mnn1O\|IhcA>?	MnT2SG1UVw>?	NX7kN3hTTUN3ME2xMlQhdk1?	MVuxPVIzOzV3Mx?=
OCUT-1	MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWqwMlEuOTByIH7N	NFLmfVE4OiCq	MmrlSG1UVw>?	M1\NUmVEPTB;Mj6zJI5O	NHvKTVcyQTJ{M{W1Ny=>
8505C	MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILUc4kxNjFvMUCwJI5O	NFLpXlI4OiCq	M1nBRWROW09?	Mn63SWM2OD1\|LkKgcm0>	NH3wOIQyQTJ{M{W1Ny=>
ACT-1	NXvDb4M2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jIPVAvOS1zMECgcm0>	Mk\IO\|IhcA>?	MWnEUXNQ	MoT0SWM2OD13LkSgcm0>	M3XKW\|E6OjJ\|NUWz
SW1736	MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYSwMlEuOTByIH7N	MlPGO\|IhcA>?	NVPUVmZOTE2VTx?=	Mo\4SWM2OD13Lk[gcm0>	MoTVNVkzOjN3NUO=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pro-caspase-8 / cleaved caspase-8 / cleaved caspase-3 / cleaved caspase-9; PubMed: 27699933 Cancer Sci PLKi‐induced caspase activation. HeLa cells were treated with BI 2536 (10 nmol/L), BI 6727 (68 nmol/L), or GSK461364 (11 nmol/L), and HCT 116 cells were treated with BI 2536 (20 nmol/L), BI 6727 (70 nmol/L), or GSK461364 (12 nmol/L) for 48 h. The levels of cleaved caspase (CASP)‐3, ‐8, and ‐9 were examined by Western blot analysis. p-HH3 / PARP / Myc / p-Myc; PubMed: 24771642 Clin Cancer Res Western blotting showing more mitotic arrested (shown by phospho-histone H3) and apoptotic (shown by PARP) cells as well as lower MYC levels in LNCaP-Pim1 cells after BI 2536 treatment compared with LNCaP-Neo cells. The difference is obvious at lower dose of BI 2536 (10 nM). Both total MYC expression and phosphor-MYC levels were lower in Pim1 cells than Neo cells after BI 2536 treatment. pMEK / MEK / pERK / ERK / pRSK1 / RSK1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and activation of components of the MEK-ERK-RSK1 pathway in MKN45 and MKN74 cancer cells treated with BI 2536 and BI 6727 for 24 and 48 hours, respectively. pPlk1 / Plk1 / pMyt1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like and cancer cells after treatment with BI 2536 and BI 6727 for 24 and 48 hours, respectively. Aurora B / pAurora B / pAurora C / pH3 / Cyclin B1 / Securin / pBcl-XL / MPM2; PubMed: 25169932 Mol Oncol Western blot analysis of cells treated for 24 h with the indicated inhibitor concentrations. Cell lysates were immunoblotted for Plk1, Phospho-Aurora B (T232)/Aurora C (T198), Aurora B, histone H3 phosphorylated at S10 (pH3), Cdk1, Cyclin B1, Securin, Phospho-Bcl-XL, Induced myeloid leukemia cell differentiation protein Mcl-1, MPM-2 and β-Actin. Left (Hela cells); Right (HUVEC)	27699933 24771642 28430578 25169932
Immunofluorescence	p-H2AX / propidium iodide; PubMed: 22309939 Breast Cancer Res Apoptotic images of the cells after BI 2536 treatment, as revealed by HCS (high-content screening) instrument (×10) with phospho-H2AX antibody or PI (propidium iodide) intake. Pericentrin / α-tubulin; PubMed: 21772266 Nat Commun MEFs were labelled using Plk1, pericentrin and α-tubulin antibodies and 4,6-diamidino-2-phenylindole for the analysis by immunofluorescence microscopy. Representative examples of BI 2536-treated and control MEFs are depicted. Scale bar, 5 μm.	22309939 21772266
Growth inhibition assay	Cell viability; PubMed: 21772266 Nat Commun Proliferative activity of MEFs at different BI 2536 concentrations (25–250 nM; means±s.d., n=3, for each concentration). P<0.05, P<0.01, **P<0.001, Student's t-test, unpaired and two-tailed.	21772266

In vivo

BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Plk1 in vitro kinase assay: Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl₂, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-³³P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:^[1]	- Collapse Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc. Concentrations: Dissolved in DMSO, final concentrations ~1 μM Incubation Time: 24 and 72 hours Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female BomTac:NMRI-Foxn1^nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells Formulation: Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl Dosages: ~50 mg/kg Administration: Injection i.v. once or twice per week (Only for Reference)

References

Solubility (25°C)

In vitro	Ethanol	100 mg/mL (191.69 mM)
	DMSO	21 mg/mL (40.25 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG 400+0.5% Tween 80+5% Propylene glycol For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BI 2536 SDF

Molecular Weight	521.66
Formula	C₂₈H₃₉N₇O₃
CAS No.	755038-02-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02215044	Terminated	Drug: BI 2536 intravenous\|Drug: Gemcitabine intravenous	Pancreatic Neoplasms	Boehringer Ingelheim	June 2007	Phase 1
NCT02211833	Completed	Drug: BI 2536\|Drug: Pemetrexed	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	October 2006	Phase 1
NCT00701766	Completed	Drug: BI 2536	Leukemia Myeloid Acute	Boehringer Ingelheim	October 2006	Phase 2
NCT00706498	Completed	Drug: BI 2536	Prostatic Neoplasms	Boehringer Ingelheim	September 2006	Phase 2
NCT00376623	Completed	Drug: BI 2536	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	July 2006	Phase 2
NCT02211872	Completed	Drug: BI 2536 BS intravenous	Neoplasms	Boehringer Ingelheim	August 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?
Answer:
For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Selective Plk Inhibitors

GSK461364 : Plk1-selective, K_i=2.2 nM.
Plk Inhibitor in Clinical Trial

Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).
Newest Plk Inhibitor

Ro3280 ^New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
Calssic Plk Inhibitor

Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

Related PLK Products

SBE 13 HCl ^New

SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
Rigosertib (ON-01910)

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.
HMN-214

HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
GSK461364

GSK461364 inhibits purified Plk1 with K_i of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.
Volasertib (BI 6727)

Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

Features:A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.
MLN0905

MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.
Ro3280

RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.
NMS-P937 (NMS1286937)

NMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536

Cited by 134 Publications

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BI 2536 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536

Cited by 134 Publications

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BI 2536 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)